Author(s)

Qian Liu¹, FeiXiong Yan¹, XiaFan Qu¹, Qiao Zhu¹, Ping He¹, BinBin Chen^2*

Affiliation(s)

¹Hunan Institute of Schistosomiasis, The Third People’s Hospital of Hunan Province, Yueyang, Hunan, China.

²Hunan Provincial People’s Hospital/The first affiliated hospital of Hunan Normal University, Changsha, Hunan, China.

Corresponding Author

BinBin Chen

ABSTRACT

Objective: To study the clinical efficacy of Xuanfei Baidu Granules combined with Western medicine in the treatment of Damp-Toxin Obstructing Lung Chronic Obstructive Pulmonary Disease (COPD).

Methods: A retrospective analysis was conducted on the data of 124 COPD patients treated at our hospital's respiratory department between July 2021 and March 2024. All patients were diagnosed with Damp-Toxin Obstructing Lung Syndrome. Of these, 64 patients treated with Western medicine alone were designated as the control group, while 60 patients treated with Xuanfei Baidu Granules combined with Western medicine were designated as the study group. The study compared Traditional Chinese Medicine (TCM) syndrome scores, lung function [Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC ratio, Airway Resistance (Raw), Peak Expiratory Flow Rate (PEFR)], 6-minute walk test (6MWT) results, COPD Assessment Test (CAT) scores, inflammation-related indicators [White Blood Cell count (WBC), Neutrophil percentage (NEUT%), Lymphocyte percentage (LYMPH%), Platelet count (PLT), Interleukin-6 (IL-6), Interleukin-17 (IL-17), C-reactive protein (CRP), Procalcitonin (PCT), Connective Tissue Growth Factor (CTGF), Transforming Growth Factor-β1 (TGF-β1)], blood gas analysis indicators [Arterial Oxygen Partial Pressure (PaO2), Carbon Dioxide Partial Pressure (PaCO2), Oxygen Saturation (SaO2), Oxygenation Index (PaO2/FiO2)], clinical efficacy, and adverse reactions between the two groups.

Results: After 5 days of treatment, the control group exhibited significantly higher scores for fever, cough with sputum, dyspnea, wheezing, abdominal distension, constipation, difficulty falling asleep, fatigue, poor appetite, and total TCM syndrome scores compared to the study group, with differences being statistically significant (P<0.05). Lung function parameters, including FEV1, FVC, FEV1/FVC ratio, PEFR, and 6MWT results, were significantly lower in the control group compared to the study group, while Raw and COPD CAT scores were significantly higher in the control group. These differences were statistically significant (P<0.01). There was no statistically significant difference in WBC counts between the two groups after 5 days of treatment (P>0.05). However, NEUT%, LYMPH%, IL-6, IL-17, CRP, PCT, CTGF, and TGF-β1 levels were significantly higher in the control group, while PLT was significantly lower compared to the study group, with differences being statistically significant (P<0.001). PaO2, PaCO2, SaO2, and PaO2/FiO2 were all significantly lower in the control group compared to the study group (P<0.001). The total effective rate in the control group was 81.25% (52/64), significantly lower than 95.00% (57/60) in the study group, with the difference being statistically significant (P<0.05). The adverse reaction rate was 10.94% (7/64) in the control group compared to 6.67% (4/60) in the study group, with no statistically significant difference (P>0.05).

Conclusion: The combination of Xuanfei Baidu Granules with Western medicine significantly improves heart and lung function, reduces TCM syndrome scores and inflammation levels, and enhances blood oxygen content and clinical efficacy in patients with damp-heat obstructing the lung type of COPD.

KEYWORDS

Xuanfei Baidu Granules; Damp-heat obstructing the lung syndrome; COPD; Cardio-pulmonary function; Traditional Chinese medicine syndrome scores

CITE THIS PAPER

Qian Liu, FeiXiong Yan, XiaFan Qu, Qiao Zhu, Ping He, BinBin Chen. Clinical study on the treatment of chronic obstructive pulmonary disease with damp-toxin obstructing lung syndrome using Xuanfei Baidu granules combined with western medicine.  Journal of Pharmaceutical and Medical Research. 2025, 7(1): 1-10. DOI: https://doi.org/10.61784/jpmr3027.

REFERENCES

[1] Ferrera MC, Labaki WW, Han MK. Advances in Chronic Obstructive Pulmonary Disease. Annu Rev Med, 2021, 27(72): 119-134.

[2] Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med, 2022, 10(5): 497-511.

[3] Lange P, Colak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med, 2016, 4(6): 454-462.

[4] Emeryk A, Emeryk-Maksymiuk J. Short-acting inhaled β2-agonists: why, whom, what, how? Adv Respir Med, 2020, 88(5): 443-449.

[5] Amegadzie JE, Gamble JM, Farrell J, et al. Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis, 2022, 20(17): 1205-1217.

[6] Wei YP, Wang JM, Dong XY. Wang Youkui's treatment of chronic obstructive pulmonary disease from the Five viscera and five Elements based on "Lung-gui theory" . Journal of Zhejiang Chinese Medicine University, 2023, 47(8): 869-873.

[7] Kahnert K, Jorres RA, Behr J, Welte T. The Diagnosis and Treatment of COPD and Its Comorbidities. Dtsch Arztebl Int, 2023, 120(25): 434-444.

[8] Chen LC, Chen XS, WU XH, et al. Systematic evaluation of distribution of traditional Chinese medicine syndromes of novel coronavirus pneumonia. Pharmacology and Clinic of Traditional Chinese medicine, 2020, 36(2): 46-50.

[9] Dai GC, Zhang XG, Gao WW, et al. Yinqiao Powder combined with Sanren Decoction in the treatment of 20 cases of common dampness-toxin pneumonitis syndrome of novel coronavirus pneumonia. Journal of Anhui College of Traditional Chinese Medicine, 2020, 39(5): 1-4.

[10] Huang JH, Bai SL, Liu R. Discussion on TCM treatment of lung diseases based on the theory of "Qi and blood" . Shaanxi Journal of Traditional Chinese Medicine, 2023, 44(4): 483-486.

[11] Zhou C, Qin Y, Zhao W, et al. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. Transl Lung Cancer Res, 2023, 12(8): 1661-1701.

[12] Mao X, Hu F, Peng J, et al. Writing Expert Group of Expert Consensus on Expert Consensus on the whole process management of lung rehabilitation in lung cancer patients undergoing surgery complicated with chronic obstructive pulmonary disease, the Lung Cancer Professional Committee of China Medical Education Association; Writing Expert Group of Expert Consensus on Expert Consensus on the whole process management of lung rehabilitation in lung cancer patients undergoing surgery complicated with chronic obstructive pulmonary disease, the Lung Cancer Professional Committee of China Medical Education Association. Expert consensus on multi-disciplinary treatment, whole-course pulmonary rehabilitation management in patients with lung cancer and chronic obstructive lung disease. Ann Palliat Med, 2022, 11(5): 1605-1623.

[13] Gao Z, Liu Y, Zhang J, et al. Effect of Jianpi therapy in treatment of chronic obstructive pulmonary disease: a systematic review. J Tradit Chin Med, 2013, 33(1): 1-8.

[14] Liu M, Xiao W, Du L, et al. Effectiveness and safety of opioids on breathlessness and exercise endurance in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomised controlled trials. Palliat Med, 2023, 37(9): 1365-1378.

[15] Huang P, Lin X, Liu Y, et al. The efficacy and safety of combined traditional Chinese and western medicine in the treatment of chronic obstructive pulmonary disease complicated with respiratory failure: a systematic review and meta-analysis study. Ann Palliat Med, 2022, 11(3): 1102-1111.

[16] Dobrowolska K, Emeryk A, Janeczek K, et al. Influence of Physicochemical Properties of Budesonide Micro-Suspensions on Their Expected Lung Delivery Using a Vibrating Mesh Nebulizer. Pharmaceutics, 2023, 15(3): 752.

[17] N V, Lokavarapu B R. Enhanced Optimal Parameter-Based Nebulizer Design for Flow Analysis of Fluticasone Propionate. AAPS PharmSciTech, 2023, 24(4): 85.

[18] Pang WT, Yang FW, Zheng WK, et al. Study on clinical efficacy of Xuanfeixuedu granules in the treatment of novel coronavirus pneumonia infected by Omicron strain. Tianjin Traditional Chinese Medicine, 2022, 39(9): 1093-1098.

[19] Dayuan Z, Lan L, Luhua X, et al. A bibliometric analysis of research related Chinese Medicine in the prevention and treatment of corona virus disease 2019. Heliyon, 2022, 8(11): e11120.

[20] Feng LM, Liu XY, Zhang L. Clinical efficacy of Xuanfeixuedu granules in the treatment of novel coronavirus pneumonia (Omicrone). Tianjin traditional Chinese medicine, 2022, 39(5): 545-550.

[21] Li CM, Zhang Z, Zhang YF, et al. Effects of YiQxuanfei Decoction on pulmonary function and serological indexes in patients with chronic obstructive pulmonary disease in stable stage of lung Qi deficiency. World Journal of Integrated Chinese and Western Medicine, 2020, 15(11): 2067-2071.

[22] Deng YH, Liu Y. Effect of self-prepared Qingre Xuanfei Decoction on the treatment of acute exacerbation of chronic obstructive pulmonary disease, lung function and changes of serum inflammatory factors. Thrombosis and hemostasis, 2020, 26(6): 929-931.

[23] Dai GM, Wang H. Effect of inhalation drug therapy on inflammatory factors and quality of life on stable chronic obstructive pulmonary disease. Pak J Med Sci, 2024, 40(7): 1403-1409.

[24] Chen Y, Wang Y, Li Z, et al. Exploration of the Mechanism of Shengxian Decoction Against Chronic Obstructive Pulmonary Disease Based on Network Pharmacology and Experimental Verification. Assay Drug Dev Technol, 2023, 21(6): 258-272.

[25] Deng L, Zhang X, Dong Y, et al. Erchen decoction combined with Sanziyangqin decoction for chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore), 2020, 99(40): e22315.

[26] Toller-Kawahisa JE, Hiroki CH, Silva CMS, et al. The metabolic function of pyruvate kinase M2 regulates reactive oxygen species production and microbial killing by neutrophils. Nat Commun, 2023, 14(1): 4280.

[27] Guo P, Li R, Piao TH, et al. Pathological Mechanism and Targeted Drugs of COPD. Int J Chron Obstruct Pulmon Dis, 2022, 12(17): 1565-1575.

[28] Han M, Kang R, Zhang C. Lymph Node Mapping for Tumor Micrometastasis. ACS Biomater Sci Eng, 2022, 8(6): 2307-2320.

[29] Liu T, Zhang Z, Shen W, Wu Y, Bian T. MicroRNA Let-7 Induces M2 Macrophage Polarization in COPD Emphysema Through the IL-6/STAT3 Pathway. Int J Chron Obstruct Pulmon Dis, 2023, 13(18): 575-591.

[30] Niu WH, Wu F, Cao WY, et al. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep, 2021, 41(1): BSR20202583.

[31] Henen C, Johnson EA, Wiesel S. Unleashing the Power of IL-17: A Promising Frontier in Chronic Obstructive Pulmonary Disease (COPD) Treatment. Cureus, 2023, 15(7): e41977.

[32] Ding F, Han L, Fu Q, et al. IL-17 Aggravates Pseudomonas aeruginosa Airway Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Front Immunol, 2022, 13(12): 811803.

[33] Shen YW, Zhou YD, Chen HZ, et al. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity. Trends Cancer, 2021, 7(6): 511-524.

[34] Deng Q, Song C, Liu Q. Effect of Xuanfei Xiedu Granule combined with non-invasive positive pressure ventilation on patients with acute exacerbation of chronic obstructive pulmonary disease with type II respiratory failure. Chinese Minkang Medicine, 2023, 35(24): 92-95.

[35] Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med, 2020, 41(3): 421-438.